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Abstract
Vaccine mediated immune mediated thrombocytopenia (ITP) is exceedingly
rare. We present a case of a young female who developed severe refractory ITP
with multiple bleeding sites post second dose of COVID-19 vaccination. She was
treated with a combination of romiplostim and mycophenolate mofetil that resulted in rapid platelet count recovery.
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I N T RO DU CT ION

asthma presented to the hospital with two-day history of
worsening petechiae that initially started on her face and
lower extremities and eventually spread to her back, chest,
abdomen, and upper extremities. She also complained of
intermittent epistaxis.
Vital signs on initial presentation including blood
pressure, heart rate, and oxygen saturation were normal.
Physical examination revealed extensive bruising over her
back, chest, and extremities along with scattered petechiae
all over the body. Laboratory findings on presentation included WBC of 11 × 109/L, hemoglobin (Hb) of 11 g/dl,
and severe thrombocytopenia with a platelet count of 1
× 109/L. Prothrombin time (PT/INR), activated partial
thromboplastin time (aPTT), fibrinogen, lactate dehydrogenase (LDH), absolute reticulocyte count, and haptoglobin levels were within normal limits. Peripheral blood
smear showed profound thrombocytopenia with no evidence of schistocytes. RT-PCR testing for SARS-CoV-2 infection was negative. Autoimmune and infectious workup
including antinuclear antibody (ANA), coombs testing,
HIV ELISA, and serology for hepatitis B and C were negative. Ultrasound of the abdomen did not show evidence of
splenomegaly or liver parenchymal changes.

Immune-mediated thrombocytopenia (ITP) is an autoimmune condition characterized by low platelet counts and
wide range of clinical manifestations from asymptomatic
presentation to major bleeding manifestations. Vaccine-
mediated secondary ITP is rare and is associated with influenza, measles mumps rubella (MMR), and hepatitis A
and B vaccination. Most patients respond to steroids and
intravenous immunoglobulin (IVIG).1 We hereby report a
case of a 26-year-old woman with severe refractory ITP who
presented with multiple active bleeding sites leading to a
significant drop in hemoglobin post second dose of mRNA-
1273 SARS-CoV-2 vaccine. She was refractory to treatment
with steroids and IVIG and was eventually treated with
combination of romiplostim and mycophenolate mofetil
(MMF) with which her counts improved dramatically.
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A 25-year-old Caucasian woman with no significant
past medical history except for well-controlled bronchial
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Her most recent laboratory testing including Hb and
platelet count from three months ago during routine primary care visit, was within normal limits. She neither reported personal or family history of bleeding disorders nor
had required blood transfusions prior to this presentation.
26 days prior to this presentation, she had received her
second dose of mRNA-1273 SARS-CoV-2 vaccine.
Given her clinical presentation, negative infectious and
autoimmune workup, normal hemolysis and coagulation
studies along with absence of other identifiable underlying etiology, she was diagnosed with ITP and was initiated
on dexamethasone 40 mg daily for four days along with
IVIG 1 g/kg for two days. She continued to have clinical
worsening during the second and third day of hospitalization and developed multiple bleeding sites including
gross hematuria, hematochezia, and subconjunctival
hemorrhage. Her hemoglobin dropped from 11 g/dl on
presentation to 6.4 g/dl. She was initiated on tranexamic
acid for bleeding control and supportive care with platelet
transfusions. Her platelet counts continued to remain low
(5 × 109/L) despite receiving 4 days of dexamethasone, 2
days of IVIG, and platelet transfusion support. She continued to have intermittent epistaxis; however, hematuria
and rectal bleeding started improving with tranexamic
acid initiation.
As there was no improvement in platelet counts with
IVIG and dexamethasone, on day 7, she was initiated on
MMF 1 g twice daily and romiplostim 1 mcg/kg weekly.
On day 12, her platelet counts for the first time improved
to 13 × 109/L. Hb remained stable around 11 g/dl. She was
discharged after receiving second dose of romiplostim 3
mcg/kg on day 14. During her first outpatient visit on day
21, her platelet counts improved to 140 × 109/L. She went
on to receive third dose of romiplostim at 3 mcg/kg. She
had no evidence of active bleeding. During fourth week
follow-up, platelet count recovered to 268 × 109/L and
MMF was tapered down to 500 mg twice daily and romiplostim to 2 mcg/kg. By fifth-week, her platelet counts
continued to improve to 324 × 109/L and MMF was tapered to 250 mg twice daily and romiplostim to 1 mcg/kg.
She continued to have normal and stable platelet counts,
and eventually, MMF and romiplostim were discontinued
at her sixth-week follow-up visit. She continued follow-up
in the hematology clinic for 3 months from discharge from
the hospital after which she was advised to resume care
with her primary care physician.
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ITP is an autoimmune entity characterized by autoantibodies directed against platelet antigens leading to platelet destruction and thrombocytopenia. Clinical manifestations
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range from asymptomatic presentation, spontaneous petechiae and purpura, mucocutaneous hemorrhage to fatal
complications such as gastrointestinal bleeding or intracranial hemorrhage, which usually occur when platelet
count is below 10 × 109/L.2
Vaccination as an etiology for secondary ITP was
previously reported with influenza, hepatitis A and B,
measles, MMR, and diphtheria tetanus acellular pertussis (DTaP) vaccines. It is hypothesized that pathogenesis of ITP is mainly secondary to molecular mimicry,
a phenomenon in which host antigens are recognized
as antigens of immunization, provoking the development of autoantibodies. These antibody-coated platelets
may undergo reticuloendothelial phagocytosis resulting in reduced platelet survival. It is also proposed that
vaccine-associated autoimmunity can stem not only from
antigen-mediated responses but also contributed by other
constituents of vaccine such as adjuvants, preservatives,
or diluents.1,3
Lee et al. described 20 patients who developed thrombocytopenia after receiving COVID vaccination with either mRNA-1273 or Pfizer-BioNTech BNT16B2b2 mRNA
SARS-CoV-2 vaccine. Sixteen of these patients did not
report history of thrombocytopenia prior to their vaccination.4 Onset of symptoms from the date of vaccination
ranged from 1 to 23 days.4 In the other three individually published case reports, ITP developed 12 h to 5 days
post Pfizer-BioNTech BNT16B2b2 mRNA SARS-CoV-2
vaccine in patients who previously had a normal platelet count.5–7 Similarly, our patient had normal platelet
counts prior to this presentation. ITP developed on day
26 after the second vaccine was given, which differs from
previously reported cases and, so far, is the most “delayed” onset reported in the literature. It is not clear how
the immunologic mimicry happens after SARS-CoV2
vaccination and what the immunologic target is. Immune
responses to vaccines are highly variable between different individuals and populations, and there may be other
factors implicated such as the microbiome impact on vaccine immunity.8 Corticosteroids, IVIG with or without
platelet transfusions, have been used successfully with
responses noted within 4–6 days.5–7 In the study by Lee
et al, outcomes were reported in 16 patients, of which 13
responded to the initial treatment with IVIG, steroids,
or platelet transfusion. One patient received rituximab,
romiplostim, vincristine along with steroids and IVIG.
Another patient developed severe thrombocytopenia and
intracranial hemorrhage despite receiving corticosteroids, IVIG, and Rituximab.4
In our case, thrombocytopenia was refractory to initial treatment with dexamethasone and IVIG. Due to her
presentation with massive and multi-site bleeding, there
was concern for imminent intracranial hemorrhage in
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this young and otherwise healthy female, and a rapid
response to treatment of her refractory ITP seemed critical. We were hesitant to use commonly recommended
options for refractory ITP, such as rituximab, single-agent
thrombopoietin-stimulating agent (TSA), and spleen tyrosine kinase inhibitor fostamatinib due to acuity of this
case.9 With rituximab, median time to response is 5.5
weeks,10 and TSAs and fostamatinib are approved for
patients with chronic ITP who have failed conventional
medical therapy or splenectomy.11–13 Although promising,
there are limited data to support the use of single-agent
TSAs in newly diagnosed ITP.14 In a pooled analysis of
phase III clinical trials studying fostamatinib in patients
with chronic ITP, only 18% of patients achieved a stable
response.15 Splenectomy was prohibited due to bleeding
risk and would increase lifelong susceptibility to encapsulated bacteria.9
Promising activity for MMF in the treatment of de novo
and refractory ITP has emerged over the recent years, and
after careful consideration and extensive discussion with
the patient and her family, we decided to combine MMF
with the TSA romiplostim. The combination of immunosuppressants with IVIG and TSA has been reported in a
small series to be efficacious and safe.16,17 The response to
this combination was rapid and vigorous.
As SARS-CoV-2 pandemic persists, concerns for
vaccine-related side effects remain, both among caregivers
and the general population. As of June 26, 2021, around
46.4% of the United States population has received full
vaccination against SARS-CoV-2 and the risks of serious
adverse events remain extremely low. Similar to primary
ITP, vaccine-related ITP can have a broad spectrum of
presentation ranging from mild bleeding and petechiae to
fatal bleeding manifestations. When patients present with
ITP, a thorough vaccination history is needed. ITP after
SARS-CoV-2 vaccination is rare, and the potential association is often overlooked and missed. While neither of the
clinical trials studying mRNA-1273 or Pfizer-BioNTech
BNT16B2b2 mRNA SARS-CoV-2 vaccine had documented cases of thrombocytopenia,18 it is worthwhile to
note that possibility of reported thrombocytopenia post-
vaccination could be merely a coincidence rather than a
causative factor. Nevertheless, we are probably just now
only at the beginning of our understanding of the plethora
and complexity of side effects and immunological impact
of the SARS-CoV-2-directed vaccination and the virus
itself. Continued vigilance and reporting of the possible
side effects of vaccinations are needed, and we believe this
should not preclude individuals from getting vaccinated
given rarity of these events and the proven effectiveness of
vaccine in mitigating this horrendous pandemic.
Further studies on the aggressive management with
combination regimens including immunosuppressants
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and thrombopoietin agonists, especially among patients
with refractory thrombocytopenia and bleeding complications, are warranted.
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